Latest On Trevena, Inc (TRVN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 21:00 EST | News | Trevena regains compliance with Nasdaq listing rule | N/A |  |
| 2023-05-15 15:45 EST | News | Trevena GAAP EPS of -$0.81 | N/A | |
| 2023-05-15 15:45 EST | News | Trevena, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-15 15:45 EST | News | Trevena, Inc. (TRVN) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-08 16:12 EST | News | Trevena stock jumps ~20% as partner gets Chinese approval for pain drug Olinvyk | N/A | |
About Trevena, Inc (TRVN):
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; a read more...nd TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
General
- Name Trevena, Inc
- Symbol TRVN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Fiscal Year EndDecember
- IPO Date2014-01-31
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.trevena.com
Valuation
- Price/Sales (Trailing 12 Mt.) 87.74
- Price/Book (Most Recent Quarter) 3.27
- Enterprise Value Revenue 77.77
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.31
- Next Year EPS Estimate -$0.20
- Next Quarter EPS Estimate -$0.06
- Operating Margin -961%
- Return on Assets -21%
- Return on Equity -44%
- Revenue 3.07 million
- Earnings Per Share -$0.26
- Revenue Per Share $0.02
- Gross Profit 2.89 million
- Quarterly Earnings Growth 122.6%
Highlights
- Market Capitalization 324.16 million
- EBITDA -21353000
- Analyst Target Price $5.25
- Book Value Per Share $0.65
Share Statistics
- Shares Outstanding 157.03 million
- Shares Float 159.45 million
- % Held by Insiders 158%
- % Held by Institutions 11.65%
- Shares Short 18.73 million
- Shares Short Prior Month 18.83 million
- Short Ratio 4.57
- Short % of Float 12%
- Short % of Shares Outstanding 12%
Technicals
- Beta 2.51
- 52 Week High $3.68
- 52 Week Low $0.46
- 50 Day Moving Average 2.3
- 200 Day Moving Average 2.4
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Trevena, Inc (TRVN) Dividend Calendar:
Trevena, Inc (TRVN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Trevena, Inc (TRVN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Trevena, Inc (TRVN) Chart:
Trevena, Inc (TRVN) News:
Below you will find a list of latest news for Trevena, Inc (TRVN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Trevena, Inc (TRVN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest TRVN Trades:
Trevena, Inc (TRVN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | 8-K (Current report) | |
| 2020-11-02 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-30 | 8-K (Current report) | |
| 2020-10-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-08-11 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-02 | 8-K (Current report) | |
| 2020-05-26 | 8-K (Current report) | |
| 2020-05-18 | 8-K (Current report) | |
| 2020-05-18 | 8-K (Current report) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-15 | 4 (Statement of changes in beneficial ownership of securities) | |
Trevena, Inc (TRVN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Trevena, Inc (TRVN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 158%
Institutional Ownership: 1165%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-10 | Scott Applebaum | CLCO; SVP Regulatory Affairs | Buy | 250,000.00 | 250,000.00 | | ||
| 2019-12-12 | Robert T Yoder | Sr. VP, Chief Business Officer | Buy | 167,000.00 | 253,254.00 | | ||
| 2019-12-12 | Mark Demitrack | Sr. VP & Chief Medical Officer | Buy | 213,000.00 | 320,038.00 | | ||
| 2019-12-12 | Barry Shin | Chief Financial Officer | Buy | 194,000.00 | 469,000.00 | | ||
| 2019-12-12 | Carrie L. Bourdow | President and CEO | Buy | 657,000.00 | 925,894.00 | | ||
| 2019-06-25 | Barry Shin | Chief Financial Officer | Buy | 275,000.00 | 275,000.00 | | ||
| 2019-05-31 | John P. Hamill | VP Fin,Princ Fin&Acct Officer | Buy | 7,500.00 | 1.16 | 8,700.00 | 87,750.00 | |
| 2019-02-01 | LEON O JR MOULDER | Director | Buy | 100,000.00 | 1.02 | 102,000.00 | 100,000.00 | |
| 2019-02-01 | Carrie L. Bourdow | President and CEO | Buy | 50,000.00 | 1.02 | 51,000.00 | 304,500.00 | |
| 2019-02-01 | MAXINE GOWEN | President & CEO | Buy | 50,000.00 | 1.02 | 51,000.00 | 54,000.00 | |
| 2018-12-06 | Robert T Yoder | Sr. VP, Chief Business Officer | Buy | 100,000.00 | 100,000.00 | | ||
| 2018-12-06 | Mark Demitrack | Sr VP & Chief Medical Officer | Buy | 125,000.00 | 125,000.00 | | ||
| 2018-12-06 | Carrie L. Bourdow | President and CEO | Buy | 250,000.00 | 254,500.00 | | ||
| 2018-12-06 | John P. Hamill | VP Fin,Princ Fin&Acct Officer | Buy | 80,000.00 | 80,250.00 | |